Loading clinical trials...
Loading clinical trials...
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Conditions
Interventions
Macimorelin
Insulin
Locations
27
United States
Harbor UCLA Medical Center
Torrance, California, United States
Texas Diabetes and Endocrinology
Austin, Texas, United States
Baylor College of Medicine-Endocrinology
Houston, Texas, United States
VA Puget Sound Health Care System
Seattle, Washington, United States
Swedish Medical Center - Cherry Hill
Seattle, Washington, United States
Krankenanstalt Rudolfstiftung
Vienna, Austria
Start Date
December 3, 2015
Primary Completion Date
November 29, 2016
Completion Date
November 29, 2016
Last Updated
April 10, 2018
Lead Sponsor
AEterna Zentaris
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions